{"id":"NCT00412984","sponsor":"Bristol-Myers Squibb","briefTitle":"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation","officialTitle":"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12-31","primaryCompletion":"2011-05-25","completion":"2011-05-25","firstPosted":"2006-12-19","resultsPosted":"2013-04-29","lastUpdate":"2018-07-03"},"enrollment":20976,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Atrial Fibrillation","Atrial Flutter"],"interventions":[{"type":"DRUG","name":"warfarin","otherNames":["Coumadin","BMS-565793"]},{"type":"DRUG","name":"apixaban","otherNames":["BMS-562247"]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.","primaryOutcome":{"measure":"Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period","timeFrame":"Time to first event in \"Intended Treatment Period\": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding).","effectByArm":[{"arm":"Apixaban","deltaMin":159,"sd":null},{"arm":"Warfarin","deltaMin":173,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":null},"locations":{"siteCount":1111,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Hong Kong","Hungary","India","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Norway","Peru","Philippines","Poland","Puerto Rico","Romania","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["37506747","36990261","35570249","34358298","33741689","33292046","32984892","32865097","32616154","32350915","32164888","32160801","31896036","31747786","31474328","30907005","30790160","30773022","30579505","30487982","30209126","30092948","29871978","29447773","29419390","29385429","29352007","29122636","29089455","29069359","28645934","28356246","28355434","28096100","27798052","27569438","27463942","27438322","27306620","27056738","26920728","26839066","26627878","26371113","26106009","25499871","25451868","25320240","25294786","24226808","24211508","24055845","24016507","24016506","23640971","23575255","23563134","23036896","22572202","21870978"],"seeAlso":["http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx","http://bms.com/studyconnect/Pages/home.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":3182,"n":9088},"commonTop":["Nasopharyngitis","Dizziness","Oedema peripheral","Dyspnoea","Epistaxis"]}}